Please assess the completion status of the following clinical trial:

Trial Title: Phosphodiesterase-5 (PDE5) Inhibition and Pulmonary Hypertension in Diastolic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* LVEF \>50%~* sinus rhythm and stable clinical condition defined as no changes in therapeutic regimen, or hospitalization in the 6 months preceding recruitment.~* pulmonary artery systolic pressure \> 40 mm Hg,~Exclusion Criteria:~* Patients receiving nitrates~* A history of pulmonary disease~* Alternative causes of PH other than cardiac-related~* Renal failure (creatinine \> 2mg/dL)~* Anemia~* Pericardial disease~* Cardiac amyloidosis

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sildenafil (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).